- TTR Franchise Revenue Surpasses Expectations: Generated $724 million in Q3, reflecting 135% year-over-year growth driven by the AMVUTTRA CM U.S. launch.
- Total Product Revenues Exceed 100% Growth: Reached $851 million for the quarter, up 103% from 2024, with TTR contributing 85% of total product sales.
- Collaboration and Royalty Revenue Surge: Collaboration revenue hit $352 million, while royalty income doubled to $46 million year-over-year.
- Upgraded 2025 Revenue Guidance: Raised net product revenue forecast to $2.95–$3.05 billion (from $2.65–$2.8 billion), reflecting 10% midpoint increase.
- Phase III Pipeline Expansion: Initiated two pivotal trials—ZENITH (zilebesiran for hypertension) and TRITON-PN (nucresiran for hATTR-PN)—advancing RNAi therapeutics into new therapeutic areas.
Revenue Growth and Guidance
The company's revenue growth was driven by the strong performance of its TTR franchise, with global TTR net revenues reaching $724 million, up 33% versus the prior quarter. Alnylam has increased its total net product revenue guidance for 2025 to a revised range of $2.95 billion to $3.05 billion, representing an increase of $275 million or 10% at the midpoint. Analysts estimate next year's revenue growth at 44.9%, indicating a strong outlook for the company.
Valuation Metrics
Alnylam's current valuation metrics indicate a high growth expectation. The company's P/S Ratio is 18.62, and the EV/EBITDA ratio is 231.57, suggesting that the market is pricing in significant future growth. The ROE is 26.13%, indicating a strong return on equity. However, the ROIC is -4.8%, suggesting that the company's investments are not yet generating returns. The current P/E Ratio is 1375.99, which is extremely high, indicating that the stock may be overvalued.
Pipeline Progress and Future Prospects
Alnylam is making significant progress with its pipeline, including the initiation of two new Phase III trials: the ZENITH Phase III cardiovascular outcomes trial of zilebesiran in hypertension and the TRITON-PN study of nucresiran in hATTR-PN. The company is also advancing its zilebesiran program in hypertension, which represents a significant opportunity to address major shortcomings of existing antihypertensive therapies. As Tolga Tanguler noted, "We're exceptionally well positioned within the expected category growth. We are well differentiated in terms of our mechanism, and we are continuing to invest in the category."
Conclusion on Financial Health
The company's financial health is strong, with $2.7 billion in cash, cash equivalents, and marketable securities. Alnylam has raised $600 million via new convertible notes and entered a $500 million revolving credit facility, providing significant financial flexibility. The company's non-GAAP operating income was $476 million, a $507 million increase from last year, driven by strong top-line results and revenue from collaborations.